Table 2.
Differences in Clinical Characteristics Between Cancer Survivors With (n=426) and Without (n=197) Chemotherapy-Induced Neuropathy (CIN)
| Characteristic | No CIN (1) 31.6% (n=197) |
CIN (2) 68.4% (n=426) |
Test, p-value |
|---|---|---|---|
| Mean (SD) | Mean (SD) | ||
| Karnofsky Performance Status score | 91.20 (9.33) | 83.22 (10.21) | t=9.51, <.001 |
| Body mass index (kg/m2) | 24.85 (5.03) | 26.56 (5.55) | t=−3.63, <.001 |
| Number of comorbidities | 1.47 (1.35) | 2.02 (1.48) | t=−4.46, <.001 |
| Self-Administered Comorbidity Questionnaire score |
2.87 (2.96) | 4.20 (3.39) | t=−4.99, <.001 |
| Alcohol Use Disorders Identification Test score |
2.85 (2.50) | 2.24 (2.20) | t=3.05, .002 |
| Years since cancer diagnosis | 4.40 (4.82) | 4.82 (4.84) | t=−1.01, .311 |
| Number of prior cancer treatments | 3.32 (0.98) | 3.12 (0.97) | t=2.37, .018 |
| Number of current cancer treatments | 0.46 (0.60) | 0.41 (0.59) | t=0.86, .392 |
| Number of metastatic sites (out of 7) | 0.70 (0.75) | 0.75 (0.78) | t=−0.67, .503 |
| Number of metastatic sites without lymph node involvement |
0.16 (0.52) | 0.22 (0.57) | t=−1.29, .198 |
| % (n) | % (n) | ||
| Smoker (ever) | 33.0 (64) | 37.8 (160) | FE, .279 |
| Exercise on a regular basis (% yes) | 87.2 (170) | 85.9 (365) | FE, .707 |
| Born prematurely (% yes) | 1.1 (2) | 6.6 (26) | FE, .002 |
| Surgery on arms (% yes) | 17.9 (35) | 21.5 (91) | FE, .335 |
| Surgery on hands (% yes) | 8.2 (16) | 10.6 (45) | FE, .387 |
| Surgery on legs (% yes) | 21.8 (42) | 24.7 (103) | FE, .475 |
| Surgery on feet (% yes) | 15.0 (29) | 17.0 (71) | FE, .638 |
| Injury to arms (% yes) | 25.8 (50) | 26.3 (110) | FE, .992 |
| Injury to hands (% yes) | 23.7 (45) | 34.7 (143) | FE, .008 |
| Injury to legs (% yes) | 18.8 (36) | 22.4 (93) | FE, .338 |
| Injury to feet (% yes) | 26.7 (51) | 27.9 (115) | FE, .770 |
| Comorbid conditions (% yes) | |||
| Osteoarthritis | 16.8 (33) | 30.3 (129) | FE, <.001 |
| Back pain | 23.9 (47) | 34.7 (148) | FE, .007 |
| Depression | 17.3 (34) | 23.9 (102) | FE, .061 |
| High blood pressure | 19.8 (39) | 26.5 (113) | FE, .072 |
| Heart disease | 4.1 (8) | 7.5 (32) | FE, .115 |
| Diabetes | 4.6 (9) | 5.6 (24) | FE, .702 |
| Lung disease | 6.6 (13) | 4.7 (20) | FE, .339 |
| Anemia or blood disease | 4.6 (9) | 5.9 (25) | FE, .574 |
| Ulcer or stomach disease | 3.0 (6) | 3.8 (16) | FE, .817 |
| Kidney disease | 0.0 (0) | 2.3 (10) | FE, .035 |
| Liver disease | 0.0 (0) | 3.3 (14) | FE, .007 |
| Rheumatoid arthritis | 2.0 (4) | 2.8 (12) | FE, .786 |
| Pain not related to cancer | 51.8 (101) | 58.0 (246) | FE, .163 |
| Type of cancer | Χ2 = 17.41, .002 | ||
| Breast | 57.4 (113) | 54.9 (234) | |
| Colon | 4.6 (9) | 9.6 (41) | 1<2 |
| Lung | 5.6 (11) | 1.9 (8) | 1>2 |
| Ovarian | 4.6 (9) | 10.6 (45) | 1<2 |
| Other | 27.9 (55) | 23.0 (98) | |
| Any metastatic disease | 58.2 (114) | 60.2 (253) | FE, .660 |
| Chemotherapy regimen | Χ2 = 7.86, .020 | ||
| Only a platinum compound | 28.6 (56) | 22.3 (95) | |
| Only a taxane compound | 51.0 (100) | 46.9 (200) | 1<2 |
| Both a platinum and a taxane compound |
20.4 (40) | 30.8 (131) | |
| Dose of platinum compound for patients who received only a platinum (mg) |
778.94 (563.32) | 1323.95 (923.29) | U, <.001 |
| Dose of taxane compound for patients who received only a taxane (mg) |
1113.11 (517.80) | 1365.27 (1172.54) | U, .010 |
| Dose of drugs for patients who received both a platinum and a taxane compound |
|||
| Platinum dose (mg) | 2845.75 (1341.27) | 3224.51 (1469.18) | U, .072 |
| Taxane dose (mg) | 1223.01 (564.85) | 1625.18 (883.10) | U, .008 |
| Patients who had a dose reduction or delay due to neuropathy (% (n)) |
1.6 (3) | 13.8 (56) | FE, <.001 |
Abbreviations: FE = Fisher’s Exact test, kg = kilograms, m2 = meters squared, mg = milligrams, U = Mann Whitney U test, SD = standard deviation